Top Markets
#1 MON MON +2,760.99%
#2 $1 is all you need $1 is all you need +1,328.53%
#3 PYTHIA PYTHIA +52.39%
#4 eCash eCash +39.09%
#5 PinGo PinGo +24.63%
#6 Siren Siren +24.18%
#7 Collector Crypt Collector Crypt +23.46%
#8 SAFEcoin SAFEcoin +19.71%
#9 Janction Janction +19.66%
#10 Velvet Velvet +15.56%
Coin of the day
MON MON
Ustawienia
Język
POLSKI
Waluta
USD
Motyw
Sensorion SA Sensorion SA

Sensorion SA

ALSEN
Pozycja w akcjach #13334
Sensorion SA, a clinical-stage biopharmaceutical company, develops drug... Sensorion SA, a clinical-stage biopharmaceutical company, develops drug candidates for the treatment of inner ear disorders in France. The company develops OTOF-GT, a gene therapy development program to restore hearing in people living with Otoferlin deficiency; USHER-T1-GT, a gene therapy development program to for patients suffering from usher syndrome Type 1; and SENS-401, a drug candidate to treat sudden sensorineural hearing loss. Its pipeline also includes various products in development stage for restoring, treating, and preventing inner ear related disorders. The company has a collaboration agreement with Institut Pasteur for gene therapy program for pediatric and adult deafness; and with Sonova Holding AG to introduce genetic analysis for routine diagnosis of progressive hearing loss in adults through a combination of advanced therapeutic interventions and traditional hearing aids. Sensorion SA was founded in 2009 and is headquartered in Montpellier, France.
Cena akcji
$0.30840035
Kapitalizacja rynkowa
$94.37M
Zmiana (1 dzień)
0.00%
Zmiana (1 rok)
-34.60%
Kraj
FR
Handel Sensorion SA (ALSEN)

Kategoria

Healthcare
Zyski dla Sensorion SA (ALSEN)
Zyski w Dec 2025 TTM: $-40.05M
Według najnowszych raportów finansowych Sensorion SA, obecny zysk firmy wynosi $-40.05M. W roku 2023 firma osiągnęła zysk w wysokości $-24.06M, wzrost w porównaniu do zysku z roku 2022, który wynosił $-29.06M. Wyświetlany zysk to zysk przed odsetkami i podatkami, czyli EBIT.
Historia zysków firmy Sensorion SA od 2011 do 2026
Zyski na koniec każdego roku
Rok Zyski Zmień
2026 (TTM) $-40.05M 48.91%
2024 $-26.89M 11.77%
2023 $-24.06M -17.20%
2022 $-29.06M 40.87%
2021 $-20.63M 56.49%
2020 $-13.18M -19.26%
2019 $-16.33M 15.05%
2018 $-14.19M 22.11%
2017 $-11.62M 21.72%
2016 $-9.55M 64.80%
2015 $-5.79M 55.42%
2014 $-3.73M 64.62%
2013 $-2.26M 73.88%
2012 $-1.30M 56.52%
2011 $-832.10K 0.00%
Zyski podobnych firm lub konkurentów
Firma Zyski Różnica w zyskach Kraj
Novo Nordisk A/S Novo Nordisk A/S
Novo Nordisk A/S
NVO.US
$24.72B -61,819.42%
DK
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.17B -12,998.66%
US
Regeneron Pharmaceuticals, Inc. Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
REGN.US
$5.16B -12,976.69%
US
UCB SA UCB SA
UCB SA
UCB.BR
$2.14B -5,437.79%
BE
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.66B -4,233.76%
NL